The importance of circular RNAs (circRNAs) in pathological processes like cancer is evident. Among the circRNAs, recent studies have brought circPVT1 under focus as the most potent oncogenic non-coding RNA. Recent studies on various aspects of circPVT1, including its biogenesis, molecular alteration and its probable role in oncogenesis, have been conducted for research and clinical interest. In this review, a first attempt has been made to summarise the available data on circPVT1 from PubMed and other relevant databases with special emphasis on its role in development, progression and prognosis of various malignant conditions. CircPVT1 is derived from the same genetic locus encoding for long non-coding RNA lncPVT1; however, existing literature suggested circPVT1 and lncPVT1 are transcripted independently by different promoters. The interaction between circRNA and microRNA has been highlighted in majority of the few malignancies in which circPVT1 was studied. Besides its importance in diagnostic and prognostic procedures, circPVT1 seemed to have huge therapeutic potential as evident from differential drug response of cancer cell line as well as primary tumors depending on expression level of the candidate. circPVT1 in cancer therapeutics might be promising as a biomarker to make the existing treatment protocol more effective and also as potential target for designing novel therapeutic intervention.
- non-coding rna. circular pvt1. oncogenesis. mirna sponge. clinical importance
Statistics from Altmetric.com
JA and SC contributed equally.
Handling editor Professor Des Richardson.
Correction notice This article has been corrected since it was published Online First. Figure 2 has been replaced to avoid duplication of the figure legend in the image.
Contributors JA did data collection, data interpretation and wrote the manuscript. SC did study design. SD and SB did data collection, data interpretation and review of literature. AD did data interpretation and wrote the manuscript. AG did study design, data interpretation, manuscript preparation and approved the final version of the manuscript.
Funding Financial support for this work was provided by Department of Higher Education Science and Technology and Biotechnology (793(Sanc.)/ST/P/S&T/1G-2/2016, Dt. 06/12/2016) to AG.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.